Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Retained Earnings (2019 - 2025)

Allogene Therapeutics' Retained Earnings history spans 7 years, with the latest figure at $235000.0 for Q3 2025.

  • For Q3 2025, Retained Earnings rose 49.68% year-over-year to $235000.0; the TTM value through Sep 2025 reached $235000.0, up 49.68%, while the annual FY2024 figure was -$89000.0, 90.68% up from the prior year.
  • Retained Earnings for Q3 2025 was $235000.0 at Allogene Therapeutics, up from -$45000.0 in the prior quarter.
  • Across five years, Retained Earnings topped out at $235000.0 in Q3 2025 and bottomed at -$1.9 billion in Q1 2025.
  • The 5-year median for Retained Earnings is -$9.9 million (2022), against an average of -$443.4 million.
  • The largest annual shift saw Retained Earnings soared 106.51% in 2024 before it plummeted 202656.85% in 2025.
  • A 5-year view of Retained Earnings shows it stood at -$903.3 million in 2021, then surged by 98.9% to -$9.9 million in 2022, then soared by 90.38% to -$955000.0 in 2023, then skyrocketed by 90.68% to -$89000.0 in 2024, then skyrocketed by 364.04% to $235000.0 in 2025.
  • Per Business Quant, the three most recent readings for ALLO's Retained Earnings are $235000.0 (Q3 2025), -$45000.0 (Q2 2025), and -$1.9 billion (Q1 2025).